Genmab A/S ADS (GMAB)

FairStock Score: 67/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a value investor, I start with the business. Genmab develops antibody-based cancer therapies and already markets EPKINLY, TEPKINLY, and Tivdak, so it is not just a story stock. In the latest quarter, fiscal Q2 2026, revenue was $1.2 billion and net income was $303.0 million, a 26.23% margin. That is a real, profitable enterprise. Trailing free cash flow is $868.0 million, a 5.2% yield on the $16.7 billion market cap, and return on equity is 14.00%. Those are respectable, though return on capital employed at 8.79% is only modest. The balance sheet shows debt-to-equity of 0.89 and an Altman Z-Score of 2.38, so I would want more cushion. The profit growth figure of -72.82% is a red flag; the supplied revenue growth of 25.31% is encouraging, but earnings are volatile. At the 2026-10-13 close of $36.57, the P/E is 29.02, P/B is 3.66, and EV/EBITDA is 16.11. That is not a classic Graham bargain. However, the Graham Number is $52.43, giving a 30.25% margin of safety, and the Piotroski F-Score is 6/9. FairStock's Lynch category is none because only 0 years of filed results are available, so I cannot lean on a growth label. Overall, this looks like a quality biotech with cash generation, but the earnings decline and full-ish valuation demand patience and a margin of safety.

In plain English: Genmab makes antibody-based cancer medicines. The company is profitable and produces cash, but profits have taken a sharp hit and it uses a fair amount of debt. At the recent price, the shares look roughly fair or slightly cheap compared with the company's earnings and asset value, though not a screaming bargain.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer